[{'address1': '655 Elizabeth Street', 'city': 'Melbourne', 'state': 'VIC', 'zip': '3000', 'country': 'Australia', 'phone': '61 3 9389 1911', 'fax': '61 3 9389 1434', 'website': 'https://www.csl.com.au', 'industry': 'Biotechnology', 'industryKey': 'biotechnology', 'industryDisp': 'Biotechnology', 'sector': 'Healthcare', 'sectorKey': 'healthcare', 'sectorDisp': 'Healthcare', 'longBusinessSummary': 'CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.', 'fullTimeEmployees': 32698, 'companyOfficers': [{'maxAge': 1, 'name': 'Dr. Paul F. McKenzie Ph.D.', 'age': 57, 'title': 'MD, CEO & Executive Director', 'yearBorn': 1966, 'fiscalYear': 2024, 'totalPay': 6442519, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI', 'age': 58, 'title': 'Chief Financial Officer', 'yearBorn': 1965, 'fiscalYear': 2024, 'totalPay': 3026941, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andy  Schmeltz', 'age': 52, 'title': 'Executive Vice President of CSL Behring Business Unit', 'yearBorn': 1971, 'fiscalYear': 2024, 'totalPay': 2181491, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Dehring', 'title': 'Head of Investor Relations', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gregory  Boss B.S., BS(Hons), J.D.', 'age': 62, 'title': 'Executive VP of Legal & General Counsel', 'yearBorn': 1961, 'fiscalYear': 2024, 'totalPay': 1613512, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Christina  Hickie', 'title': 'Senior Manager of Communications', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Roanne  Parry', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karen  Etchberger', 'age': 65, 'title': 'Executive Vice President of Quality & Business Services', 'yearBorn': 1958, 'fiscalYear': 2024, 'totalPay': 1518425, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jemimah  Brennan', 'title': 'Head of Communications - Asia Pacific', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.', 'age': 61, 'title': 'Senior Vice President of Research', 'yearBorn': 1962, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}], 'auditRisk': 4, 'boardRisk': 4, 'compensationRisk': 4, 'shareHolderRightsRisk': 1, 'overallRisk': 2, 'governanceEpochDate': 1725148800, 'compensationAsOfEpochDate': 1735603200, 'maxAge': 86400, 'priceHint': 2, 'previousClose': 299.87, 'open': 301.73, 'dayLow': 299.87, 'dayHigh': 301.85, 'regularMarketPreviousClose': 299.87, 'regularMarketOpen': 301.73, 'regularMarketDayLow': 299.87, 'regularMarketDayHigh': 301.85, 'dividendRate': 4.0, 'dividendYield': 0.013300001, 'exDividendDate': 1725840000, 'payoutRatio': 0.4518, 'fiveYearAvgDividendYield': 1.11, 'beta': 0.325, 'trailingPE': 36.77778, 'forwardPE': 28.632128, 'volume': 271983, 'regularMarketVolume': 271983, 'averageVolume': 684949, 'averageVolume10days': 651865, 'averageDailyVolume10Day': 651865, 'bid': 301.22, 'ask': 301.21, 'marketCap': 145847992320, 'fiftyTwoWeekLow': 228.65, 'fiftyTwoWeekHigh': 313.55, 'priceToSalesTrailing12Months': 9.854594, 'fiftyDayAverage': 305.5316, 'twoHundredDayAverage': 289.58566, 'trailingAnnualDividendRate': 2.64, 'trailingAnnualDividendYield': 0.008803816, 'currency': 'AUD', 'enterpriseValue': 157476995072, 'profitMargins': 0.17851, 'floatShares': 482986940, 'sharesOutstanding': 484207008, 'heldPercentInsiders': 0.00302, 'heldPercentInstitutions': 0.35688, 'impliedSharesOutstanding': 484207008, 'bookValue': 35.929, 'priceToBook': 8.383478, 'lastFiscalYearEnd': 1719705600, 'nextFiscalYearEnd': 1751241600, 'mostRecentQuarter': 1719705600, 'earningsQuarterlyGrowth': 0.298, 'netIncomeToCommon': 2641999872, 'trailingEps': 8.19, 'forwardEps': 10.52, 'pegRatio': 1.0, 'lastSplitFactor': '3:1', 'lastSplitDate': 1192665600, 'enterpriseToRevenue': 10.64, 'enterpriseToEbitda': 34.101, '52WeekChange': 0.12340319, 'SandP52WeekChange': 0.23285389, 'lastDividendValue': 2.202978, 'lastDividendDate': 1725840000, 'exchange': 'ASX', 'quoteType': 'EQUITY', 'symbol': 'CSL.AX', 'underlyingSymbol': 'CSL.AX', 'shortName': 'CSL FPO [CSL]', 'longName': 'CSL Limited', 'firstTradeDateEpochUtc': 770342400, 'timeZoneFullName': 'Australia/Sydney', 'timeZoneShortName': 'AEST', 'uuid': '9a3996a4-16a4-3edf-aaf9-c1405a0ea0fc', 'messageBoardId': 'finmb_881503', 'gmtOffSetMilliseconds': 36000000, 'currentPrice': 301.21, 'targetHighPrice': 496.98, 'targetLowPrice': 234.42, 'targetMeanPrice': 327.3, 'targetMedianPrice': 320.46, 'recommendationMean': 2.1, 'recommendationKey': 'buy', 'numberOfAnalystOpinions': 14, 'totalCash': 1656999936, 'totalCashPerShare': 3.429, 'ebitda': 4617999872, 'totalDebt': 12183000064, 'quickRatio': 0.894, 'currentRatio': 2.175, 'totalRevenue': 14800000000, 'debtToEquity': 62.796, 'revenuePerShare': 30.641, 'returnOnAssets': 0.06558, 'returnOnEquity': 0.14581001, 'freeCashflow': 1038249984, 'operatingCashflow': 2764000000, 'earningsGrowth': 0.307, 'revenueGrowth': 0.101, 'grossMargins': 0.52061003, 'ebitdaMargins': 0.31203, 'operatingMargins': 0.19016, 'financialCurrency': 'USD', 'trailingPegRatio': None}]